Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Booster study of 10-valent pneumococcal conjugate vaccine versus Prevenar in previously primed toddlers
2006-005891-41Phase 3
- Sponsor
- GSK
- Start
- Sep 2007
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, single-blind trial of 10-valent pneumococcal conjugate vaccine and pneumococcal 7-valent conjugate vaccine in pneumococcal disease (2 arms), sponsored by GSK. Primary endpoints: Safety, Rectal fever >39.0°C after booster vaccination and 2 more.
02
Drugs
10-valent pneumococcal conjugate vaccinepneumococcal 7-valent conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2006-005891-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005891-41.